LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's Supplemental Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results